However, with the progress of chemotherapy, TKIs do not have a good efficacy in the epidermal growth factor receptor (EGFR) mutation type of NSCLC, and it is inevitable that acquired drug resistance will occur, resulting in chemotherapy failure.7 This evidence concerns the gene EGFR and non-small cell lung carcinoma.